TCGA-CN-4741-01A-01R-1436-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.360
- G2M_CHECKPOINT+0.350
- SPERMATOGENESIS+0.300
- KRAS_SIGNALING_DN+0.240
- MITOTIC_SPINDLE+0.190
- ESTROGEN_RESPONSE_EARLY+0.170
- CHOLESTEROL_HOMEOSTASIS+0.160
- APICAL_SURFACE+0.120
- PANCREAS_BETA_CELLS+0.090
- ESTROGEN_RESPONSE_LATE+0.080
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- ANGIOGENESIS-0.450
- INTERFERON_GAMMA_RESPONSE-0.440
- MYC_TARGETS_V2-0.440
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.440
- ALLOGRAFT_REJECTION-0.430
- INTERFERON_ALPHA_RESPONSE-0.420
- IL6_JAK_STAT3_SIGNALING-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG899 | — | — | 0.865 |
| 2 | MNG214 | — | — | 0.836 |
| 3 | MDT-AP-1367 | Med | Medulloblastoma | 0.834 |
| 4 | TCGA-CR-7402-01A-11R-2016-07 | — | — | 0.832 |
| 5 | SRR13780248 | — | cohortSC | 0.829 |
| 6 | TCGA-QK-AA3J-01A-11R-A39I-07 | — | — | 0.819 |
| 7 | SRR33346951 | — | — | 0.818 |
| 8 | SRR23303774 | — | — | 0.816 |
| 9 | SRR33346963 | — | — | 0.812 |
| 10 | BS_FEV5A0HN | high-grade glioma | — | 0.809 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.350 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.240 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.190 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.090 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.070 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.050 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |